Digital Rehabilitation for COPD Patients: NICE recommends

By Staff Writer

January 26, 2024

A Focus on Long-Term Respiratory Conditions:

Chronic Obstructive Pulmonary Disease (COPD) is a long-term respiratory condition affecting over 1.17 million people in England alone. In spite of the prevalence, it’s estimated that an additional 2 million individuals remain undiagnosed. COPD, which includes chronic bronchitis and emphysema, is characterised by breathlessness, persistent coughing, wheezing, and frequent chest infections. Triggers include respiratory tract infections, smoking, and environmental pollutants.

The Impact of COPD on Hospital Admissions

Exacerbations of COPD are the second most prevalent cause of emergency hospital admissions in the United Kingdom (UK), accounting for one in eight of all hospitalisations. The increased shortness of breath or coughing that occurs as a result of these flare-ups frequently calls for immediate medical attention at a hospital.

The Role of Pulmonary Rehabilitation in COPD Management

Pulmonary rehabilitation has proven effective in the UK in managing COPD according to the National Health Service (NHS). Approximately 90% of patients who complete an in-person programme, experienced increased exercise capacity and equally important, improved quality of life. However, these programmes are currently only offered to 13% of eligible patients in the UK, predominantly those with severe COPD.

Introducing Digital Rehabilitation Technologies for COPD

The medical technologies advisory committee of National Institute for Health and Care Excellence (NICE) recommends two digital technologies, MyCOPD and SPACE for COPD, for pulmonary rehabilitation treatments. These platforms offer fitness regimens and educational sessions, enabling COPD patients to manage their condition at their convenience. While they don’t replace traditional in-person rehabilitation, they offer a valuable option for individuals without access to local facilities and to those who prefer not to have in-person treatment. 

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.